Amgen Inc (FRA:AMG)
€ 283.45 -18.25 (-6.05%) Market Cap: 150.69 Bil Enterprise Value: 198.90 Bil PE Ratio: 38.26 PB Ratio: 21.34 GF Score: 90/100

Amgen Inc Investor Call Transcript

Dec 05, 2022 / 01:00PM GMT
Release Date Price: €268.9 (-1.38%)
Operator

Hello, and welcome. My name is Alex, and I will be your conference facilitator today for the Amgen analyst and investor conference call from the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference. (Operator Instructions) I would now like to introduce David Reese, Executive Vice President of Research and Development. Dr. Reese, you may now begin.

David M. Reese
Amgen Inc. - EVP of Research & Development

Thanks, Alex, and good morning, everyone. Thanks for joining us for an update on the AMG 133 program in obesity and allied disorders. These are review of data just presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

Next slide, please. Here's our standard safe harbor disclaimer. I did note that these slides are up on our website now for those who wish to follow along.

Next slide, please. In terms of today's agenda, I will provide a brief introduction to our strategy in obesity and allied disorders following which Narimon, the Head of our cardiometabolic group in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot